Amgen Inc. AMGN
465.67 USD -1.39 (-0.30%)
At closeNov 13, 2026, 5:25 PM EST
465.67 0.00 0.00%
After hours · Nov 13, 5:25 PM ET
462.22 Day range 468.00
312.39 52-week range 483.99
- YTD
- +42.27%
- 1 year
- +38.59%
News
fool.com Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into…
benzinga.com Here’s How Much You Would Have Made Owning Amgen Stock In The Last 15 Years Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 2.25% on an annualized basis producing an average annual return of 15.31%. Currently, Amgen has a market capitalization of…
benzinga.com Argus Research Maintains Buy on Amgen, Raises Price Target to $515 Argus Research analyst Jasper Hellweg maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $460 to $515.
benzinga.com Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears Amgen Inc. (NASDAQ:AMGN) announced positive Phase 3 results showing dazodalibep significantly reduced systemic disease activity and key symptoms in patients with Sjögren's disease, a chronic…
benzinga.com Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears Amgen reported positive Phase 3 OASIZ-301 trial data for dazodalibep, showing significant reductions in systemic Sjögren's disease activity.
247wallst.com Want $7,000 in Passive Income? Buy These 3 Dividend Stocks Today Selling shares to pay the bills can wreck a retirement portfolio in a downturn. A biotech giant, a Coca-Cola bottler, and a Kansas utility offer another route, though one of them carries a payout…
reuters.com Amgen's experimental Sjogren's drug meets late-stage trial goal Amgen's experimental Sjogren's drug meets late-stage trial goal- benzinga.com Amgen Says Dazodalibep Met Primary Endpoint At Week 48 In the randomized, double-blind, placebo-controlled OASIZ-301 study, patients had a mean baseline score of 10.2 on the European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease…
prnewswire.com AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/…
247wallst.com Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? One biotech pays retirees a bigger check today, while the other carries no net debt and is growing far faster. We put Amgen and Regeneron side by side on income, valuation, and growth to see which…
247wallst.com 3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all.
prnewswire.com NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM Independent VESALIUS-CV Analysis Finds Repatha Highly Cost-Effective in High-Risk Patients Without a Prior Heart Attack or Stroke Long-Term FOURIER External-Control Analysis Shows Repatha Associated…
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
zacks.com Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
fool.com The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation These are among the best the industry has to offer.
247wallst.com Amgen's Dividend Has Grown 800% Since 2011. Here's What It Pays Today Amgen has raised its payout every year since 2011, yet the pace of those raises is cooling just as patent cliffs and drug price controls close in. One number shows whether the next raise, due soon,…
benzinga.com Freedom Broker Downgrades Amgen to Hold, Raises Price Target to $470 Freedom Broker analyst Ilya Zubkov downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and raises the price target from $450 to $470.
defenseworld.net 1,809 Amgen Inc. $AMGN Shares Acquired by Alta Advisers Ltd Alta Advisers Ltd lifted its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 85.7% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…
defenseworld.net Boston Trust Walden Corp Sells 15,695 Shares of Amgen Inc. $AMGN Boston Trust Walden Corp trimmed its holdings in Amgen Inc. (NASDAQ: AMGN) by 18.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange…
benzinga.com Leerink Partners Maintains Market Perform on Amgen, Raises Price Target to $464 Leerink Partners analyst David Risinger maintains Amgen (NASDAQ:AMGN) with a Market Perform and raises the price target from $395 to $464.
benzinga.com Guggenheim Maintains Neutral on Amgen, Raises Price Target to $435 Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $378 to $435.
benzinga.com Amgen Announces Results From Large Real-World Study Showing Treatment With Repatha Reduced Risk Of Fatal Or Nonfatal Heart Attacks By 20% Compared With Ezetimibe In People With ASCVD And Prior Statin Use Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart DiseaseResults Provide…- benzinga.com Canaccord Genuity Maintains Hold on Amgen, Raises Price Target to $440 Canaccord Genuity analyst Gary Nachman maintains Amgen (NASDAQ:AMGN) with a Hold and raises the price target from $384 to $440.
- benzinga.com Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $530 Scotiabank analyst Louise Chen maintains Amgen (NASDAQ:AMGN) with a Sector Outperform and raises the price target from $500 to $530.
- benzinga.com Citigroup Maintains Neutral on Amgen, Raises Price Target to $465 Citigroup analyst Geoff Meacham maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $405 to $465.
benzinga.com JP Morgan Maintains Neutral on Amgen, Raises Price Target to $425 JP Morgan analyst Chris Schott maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $350 to $425.
benzinga.com TD Cowen Maintains Buy on Amgen, Raises Price Target to $531 TD Cowen analyst Yaron Werber maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $452 to $531.
benzinga.com Goldman Sachs Maintains Buy on Amgen, Raises Price Target to $536 Goldman Sachs analyst Salveen Richter maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $481 to $536.
benzinga.com Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data Amgen approaches 52-week highs on Q3 earnings beats and raised 2026 guidance, while Wall Street analysts lift price targets.
benzinga.com Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $410 Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $359 to $410.- benzinga.com RBC Capital Maintains Outperform on Amgen, Raises Price Target to $470 RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $430 to $470.
- benzinga.com Truist Securities Maintains Hold on Amgen, Raises Price Target to $398 Truist Securities analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Hold and raises the price target from $380 to $398.
- benzinga.com Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $460 Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $430 to $460.
benzinga.com $1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 2.06% on an annualized basis producing an average annual return of 14.83%. Currently, Amgen has a market capitalization of…
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Rise as Democrats Take Control of Congress—AMD, AMGN, NVO in Focus (UPDATED) U.S. stocks rose on Wednesday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures advanced, following Tuesday's mixed close.
benzinga.com Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $465 Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $440 to $465.
benzinga.com Amgen Q3 2026 Earnings Call Transcript Amgen (NASDAQ:AMGN) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access…- benzinga.com Amgen Raises FY2026 Adj EPS Guidance from $22.30-$23.50 to $22.90-$23.70 vs $23.02 Est; Raises FY2026 Sales Guidance from $38.200B-$39.400B to $38.900B-$39.700B vs $38.936B Est Amgen (NASDAQ:AMGN) raises FY2026 Adj EPS guidance from $22.30-$23.50 to $22.90-$23.70 vs $23.02 analyst estimate. Raises FY2026 sales outlook from $38.200 billion-$39.400 billion to $38.900…
- benzinga.com Amgen Raises FY2026 GAAP EPS Guidance from $15.80-$17.08 to $18.34-$19.28 vs $15.90 Est Amgen (NASDAQ:AMGN) raises FY2026 GAAP EPS guidance from $15.80-$17.08 to $18.34-$19.28 vs $15.90 analyst estimate..
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will the S&P 500 open higher? Polymarket odds dip to 45% as Wall Street navigates Election Day, AMD earnings, and a volatile oil market.
benzinga.com AMD, Shopify On Deck Tuesday As AI Spending, Merchant Growth Face Test Advanced Micro Devices headlines Tuesday’s reports, with investors looking for evidence that AI demand can withstand a sharp pullback in the stock. Shopify, Pfizer, Eaton, Marathon Petroleum and…
benzinga.com AMD Could Swing $90.7 Billion After Earnings Seven major companies are set to report earnings Tuesday, and options traders are pricing in significant stock moves. From Pfizer’s modest 4.14% implied move to Shopify’s 13.01% swing, here’s a…
benzinga.com Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer Reed Jobs says GLP-1 drugs could help fight cancer; Yosemite fund passes $350M target.
benzinga.com Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer Amgen's Imdelltra with Imfinzi cut small-cell lung cancer death risk by 58% in Phase 3, extending median survival to 21.1 months. Read more.- benzinga.com Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $480 Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $450 to $480.
- benzinga.com Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $400 Barclays analyst Emily Field maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $380 to $400.
benzinga.com AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.- benzinga.com Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and…
- benzinga.com AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs.…
benzinga.com Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.45% on an annualized basis producing an average annual return of 14.3%. Currently, Amgen has a market capitalization of…